California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
 Available Now to Treat Severe Asthma - EconoTimes)
ASHEVILLE, N.C., Jan. 20, 2017 -- Earlier this year, the FDA has approved Nucala as add on therapy for maintenance treatment in patients with severe eosinophilic asthma in patients 12 years of age and older. It is not indicated for acute treatment of bronchospasm. Nucala is indicated for a specific subset of asthma patients that have elevated white blood cells known as eosinophils. The elevation in eosinophils needs to be greater than 150 cells/microliter at the start of treatment or greater than 300 cells/microliter anytime in the last 12 months.
Eosinophils are responsible for inflammation in some patients with asthma. Nucala is a humanized monoclonal antibody to human IL-5 (Interleukin 5) which is primarily involved in the regulation and growth of both tissue and blood eosinophils. Therefore, Nucala will block the production and survival of eosinophils. In one study, the decrease in eosinophils decreased by 84% within 4 weeks of the onset of the study. The finding was maintained throughout the treatment period. The medication is administered once monthly by injection into the subcutaneous tissue. The patients in the studies have seen a decreased in asthma exacerbation rates and hospitalizations/ER visits.
The most common side effects are local injection site reactions and possible hypersensitivity reactions. Long term studies have not been performed. The medication is administered in a physician’s office and patients should be monitored after the injection for adverse reactions. The medication is generally administered by one of Allergy Partners’ specialists such as a Board Certified Allergy/Asthma physician.
Nucala is one of several exciting new asthma therapies that are becoming available for patients with severe or difficult to control asthma. If you have severe asthma, consult with your trusted Allergy Partners physician to discuss the best treatment for you.
Allergy Partners, P.A., is the nation's largest single specialty practice with multiple locations across the United States. We strive to be recognized as leaders in the development and delivery of high-quality health care for patients with asthma & allergic disease. Our vast care network of providers work together to promote education, research & innovation in the field of allergy & asthma care.
Contact Information: Amanda Reed, Marketing and Corporate Communications Manager Allergy Partners, P.A. 828-277-1300 phone 828-277-2499 fax [email protected] www.allergypartners.com
